Most vaccines we know are preventive. You get a flu shot or a COVID shot before you get sick. The mRNA cancer vaccines making headlines right now work differently. They are given to people who already have cancer, typically after surgery has removed the tumor, with one goal in mind: keeping the cancer from coming back.
In August 2026 this field crossed a historic threshold. A personalized mRNA cancer vaccine co-developed by Moderna and Merck succeeded in a Phase 3 clinical trial, the final major hurdle before a new therapy can seek approval, for the first time ever.
What mRNA actually does
Think of mRNA (messenger RNA) as a short instruction note that tells your cells, "build this protein."
COVID vaccines used that note to carry the blueprint for a piece of the virus, the spike protein. Your cells briefly built that protein, your immune system studied it — this is what the enemy looks like — and filed it away. When the real virus showed up later, your body recognized it fast and fought back.
mRNA cancer vaccines use the same delivery trick. What's different is what's written on the note.
The wanted poster is different for every patient
Here's the core problem with cancer: cancer cells used to be your own healthy cells. They turned malignant through genetic mutations, but on the surface they still look a lot like "self," so the immune system often walks right past them. Unlike a virus, cancer doesn't look foreign.
This is where neoantigens come in. As mutations accumulate, cancer cells start producing small, abnormal protein fragments that healthy cells simply don't have. Those fragments are neoantigens, and critically, each patient's set of them is unique, like a fingerprint.
So Moderna and Merck's vaccine is built like this:
- The patient's tumor, removed during surgery, and their blood are genetically sequenced.
- Algorithms select up to 34 neoantigens unique to that patient's cancer.
- Those neoantigen blueprints are encoded into mRNA, producing a vaccine manufactured for that one patient alone.
In other words, the vaccine hands the immune system a wanted poster with the exact face of that patient's cancer on it. T cells, the immune system's patrol officers, take the poster, sweep through the body, and attack anything that matches. If a COVID vaccine is a standard-issue poster printed identically for everyone, this cancer vaccine is a custom poster printed one patient at a time.
Why pair it with Keytruda
Cancer cells are clever. Even when immune cells approach, tumors flash a molecular signal that essentially says, "I'm normal tissue, stand down." It works like a diplomatic immunity card, and it lets cancer slip away from attack.
Keytruda (pembrolizumab), a widely used immune checkpoint inhibitor, is the drug that confiscates that card.
Put the two together and the division of labor looks like this:
- The mRNA vaccine distributes the wanted poster. It tells the patrol who to hunt.
- Keytruda strips away cancer's immunity card. It makes the arrest possible.
One tells the immune system whom to catch, the other clears the way to actually catch them. That combination is exactly what this Phase 3 trial put to the test.
Why a Phase 3 win matters here
The idea of an mRNA cancer vaccine is decades old, but late-stage trials kept failing, until the COVID-19 pandemic forced mRNA technology to mature at unprecedented speed and scale.
The trial in question, INTerpath-001 (NCT05933577), is now the first Phase 3 success for any mRNA-based cancer therapy. The companies described it as the first positive Phase 3 readout for an individualized neoantigen therapy, and the first Phase 3 to show a clinically meaningful improvement over Keytruda alone in resected melanoma.
The specifics: 1,137 patients with completely resected stage IIB–IV melanoma were randomized 2:1. One group received the personalized vaccine, called intismeran autogene, plus Keytruda; the other received Keytruda alone. The combination hit its primary endpoint of recurrence-free survival (how long patients stay cancer-free) and the key secondary endpoint of distant metastasis-free survival (how long before cancer spreads to other organs).
The earlier Phase 2 trial, KEYNOTE-942, had already hinted at this. Its five-year follow-up data, presented at ASCO in 2026 and published in the Journal of Clinical Oncology, showed the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared with Keytruda alone. The Phase 3 confirmed that signal at full scale.
Which cancers are being tested right now
Melanoma delivered the first win, but the same technology is already branching out:
- Melanoma — INTerpath-001 (NCT05933577), Phase 3, positive results announced
- Non-small cell lung cancer — INTerpath-002 (NCT06077760), INTerpath-009 (NCT06623422), INTerpath-014 (NCT07513376), all Phase 3, currently recruiting
- Head and neck cancer (HPV16-related) — BioNTech's BNT113 in AHEAD-MERIT (NCT04534205), Phase 2/3, recruiting
- Pancreatic cancer — BioNTech and Genentech's autogene cevumeran in IMCODE003 (NCT05968326), Phase 2, recruiting
Research is also underway in bladder and kidney cancers. And for brain tumors like glioblastoma, mRNA vaccine research has begun as well, though it remains at an early stage with a longer road ahead.
What this means for patients
The heart of the matter is the fight against recurrence. Even after a successful surgery, microscopic cancer cells can linger invisibly in the body and resurface months or years later as recurrence or metastasis. In melanoma, most recurrences happen within the first two years after surgery. This vaccine's strategy is to point the immune system at those invisible holdouts and eliminate them before they regroup.
That said, measured expectations are essential:
- Most trials are still ongoing. Melanoma is currently the only Phase 3 success. Results in lung, head and neck, and pancreatic cancer haven't arrived yet.
- This is not yet for patients with active disease. The trial enrolled only people who were disease-free at the time of consent. Whether the vaccine can clear a tumor that is still present was never tested. Trials aimed at active disease, such as BioNTech's BNT113, are running, but results are not in.
- The goal is delaying recurrence and spread, not a cure. The risk of the cancer returning drops. The cancer does not disappear.
- The most important question, do patients live longer, isn't answered yet. Overall survival remains a secondary endpoint under continued follow-up, and the announced results come from a pre-specified interim analysis.
- Personalized manufacturing takes time and money. Because each vaccine is custom-built from an individual tumor, cost, production capacity, and access remain open challenges before broad availability.
- Regulatory review is just beginning. The companies plan to submit data to regulators. Actual approval and clinical adoption will take more time.
What is settled and what is not
mRNA cancer vaccines have cleared their first Phase 3 gate. The technology that proved itself against a pandemic is expanding from preventing infection to treating cancer, and the idea of a custom wanted poster for every patient has, for the first time, been shown to work in a large-scale trial.
There are still more questions than answers. Will it work in other cancers? Will it truly extend lives? Can cost and access be solved? Those answers will come one by one, over the next several years, from the trials running around the world right now. Healthy skepticism is warranted. But it is now clear which way this is heading.
This article summarizes publicly available clinical trial data. Decisions about individual treatment belong with a patient's own care team.